Does your pre-launch strategy really drive behaviour change?

Dorottya Okros|16th October 2019

One of the most interesting parts of a pharmaceutical launch is delving into the minds of the stakeholders to understand why they behave in the way that they do.

Through embarking on this process, we can uncover the drivers that lead healthcare professionals to make decisions, along with the influences that shape patients’ information-seeking behaviour. We embark on a journey filled with twists and turns as we come closer to the truth and uncover why stakeholders think and feel a certain way.

In order to shape the market, pharmaceutical teams have to understand the current landscape. It’s important to guarantee the customer engagement plan is on target, ensuring that the right people are engaged, at the right time and in the right way. Insights sit at the heart of this, preventing brand teams from basing their strategy on assumptions rather than facts.

Insight comes from combining a deep understanding of customers with an understanding of the market. It is about aligning customers’ needs and the needs of the business to uncover brand opportunities. While traditional market research can help you identify the unmet needs of your audience, it will not tell you why that unmet need exists in the first place and, unlike insight, it will not offer possible solutions.

In this respect, insight goes beyond traditional market research. Achieving insight means truly listening to customers to understand why they make the decisions they make in the environments they operate in.

Challenging assumptions in rare disease

In 2018, we mapped the physician’s journey when diagnosing a patient with a rare progressive disease. Approximately, five in 100,000 people are diagnosed with this illness. Due to the scarcity of the disease, patients are often misdiagnosed with other ‘mimic’ diseases that present similar symptoms

Historically, there had been no disease modifying treatment available for these patients. However, a new therapy was entering the market and the progressive nature of the illness meant it was essential for patients to receive the treatments as early as possible.

The brand team assumed the physician was using a specific diagnostic scale designed to identify the rare disease and measure progression.

However, when we interviewed doctors, they said the test was complex and laborious to use – it did not meet their needs in the clinical setting. Instead, they were using a test designed for a far more common illness.

Armed with these insights, the brand team added a secondary endpoint which clearly indicated that physicians could use an altered version of the simpler test to make a faster diagnosis. Simultaneously, the team developed core relationships with both the rare disease patient groups and also with the groups associated with the mimic disease. This helped them reach a wider network of undiagnosed patients. Additionally, a disease awareness campaign to illustrate the importance of accurate diagnosis became an integral part of the launch strategy.

“If the team had not understood why the healthcare professionals were failing to use the scale, they could not have improved the method for diagnosing the rare disease”

The brand team would have also missed the opportunity to improve drug uptake and drive further awareness of the rare disease across the wide network of patient communities.

Delivering impactful customer engagements in COVID-19

Blue Latitude Health|14th July 2020

Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.

read more

Top 5 tips for a multi-indication product launch

Sana Rahim|8th July 2020

Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.

read more

If our patients are diverse, why are clinical trials so white?

Ling Song|22nd June 2020

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.

read more